Putting GS1’s EPCIS Standards to the Test

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-04-05-2017
Volume 12
Issue 4

In a pilot program, Johnson & Johnson Supply Chain and AmerisourceBergen demonstrated how data can be transferred between two partners.

In 2016, the pharmaceutical manufacturer Johnson & Johnson Supply Chain (JJSC) and the distributor AmerisourceBergen launched a four-week pilot program to test GS1’s EPCIS standards and to see how effectively data could be transferred between the two partners. JJSC has been working on serialization for some time, and began shipping serialized product back in 2012, so both companies were fully connected, in terms of their IT, and they could try this approach with serialized product. The test simulated the real-world supply chain. 

A DataMatrix barcode was applied containing a serialized global trade item number (GTIN), batch and lot number, and expiration data for each sellable unit (whether bottle, vial, or blister), and the units were packed into cases and loaded onto pallets, while downstream vision systems and scanners read the barcode to capture all the information. EPCIS recorded events associated with the GTIN, so that AmerisourceBergen could confirm receipt of each item sent by JJSC, automatically. 

Results showed not only the viability of this approach, but its potential power. “It’s like electronic data interchange (EDI) on steroids,” says Mike Rose, vice-president, supply chain visibility at JJSC. “Over time, supply chain partners will be able to exchange a lot of critical data for additional value,” he says. The pilot ensured that all processes, from plant to warehouse and distribution channel to docks, were tracked. “It forced us to test all processes along with way. We got confirmation from our partner that everything fed back to them, from plant to distribution center, and that they were receiving relevant process data.” Rose expects to see return on investment in terms of improved inventory management and transparency in the future. “But for now, our focus remains on the patient first,” he says. 

 

 

 

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content